| Literature DB >> 35200508 |
Ilayda Firlar1,2, Mine Altunbek2, Colleen McCarthy2, Murugan Ramalingam3,4, Gulden Camci-Unal2,5.
Abstract
Chronic wounds severely affect 1-2% of the population in developed countries. It has been reported that nearly 6.5 million people in the United States suffer from at least one chronic wound in their lifetime. The treatment of chronic wounds is critical for maintaining the physical and mental well-being of patients and improving their quality of life. There are a host of methods for the treatment of chronic wounds, including debridement, hyperbaric oxygen therapy, ultrasound, and electromagnetic therapies, negative pressure wound therapy, skin grafts, and hydrogel dressings. Among these, hydrogel dressings represent a promising and viable choice because their tunable functional properties, such as biodegradability, adhesivity, and antimicrobial, anti-inflammatory, and pre-angiogenic bioactivities, can accelerate the healing of chronic wounds. This review summarizes the types of chronic wounds, phases of the healing process, and key therapeutic approaches. Hydrogel-based dressings are reviewed for their multifunctional properties and their advantages for the treatment of chronic wounds. Examples of commercially available hydrogel dressings are also provided to demonstrate their effectiveness over other types of wound dressings for chronic wound healing.Entities:
Keywords: chronic wounds; hydrogels; polymers; wound dressings; wound healing
Year: 2022 PMID: 35200508 PMCID: PMC8871490 DOI: 10.3390/gels8020127
Source DB: PubMed Journal: Gels ISSN: 2310-2861
Figure 1Wound healing stages demonstrated on the three layers of human skin. There are four- tightly controlled stages of wound healing in the human body: (A) Hemostasis is the first stage and acts as the first response when blood vessels are damaged and blood leaks into the wound area; (B) Inflammation is the second phase and involves vasodilation which helps to prevent infection by triggering the formation of a blood clot and cleaning the wound site with leukocytes; (C) Proliferation is the tissue development phase of wound healing. Granulated tissue with an extracellular matrix (ECM) composed of new connective tissue and blood vessels is formed in the presence of an appropriate amount of moisture and oxygen; (D) Re-modeling is the last stage and is regulated by differentiated myofibroblasts. The ECM of the wounded tissue is reconstituted similar to normal tissue. Many of the newly produced capillaries regress and restore the vascular density of the wound to normal. Created with BioRender.com accessed on 13 November 2021.
Chronic wound types.
| Type of Chronic Wounds | Main Reason(s) of | Main Symptoms | Refs. |
|---|---|---|---|
| Diabetic ulcers | Peripheral neuropathy | Mild pain on legs | [ |
| Pressure ulcers | Direct pressure and shearing forces | Tissue ischemia | [ |
| Arterial insufficiency ulcers | Atherosclerosis | Tissue ischemia | [ |
| Blood vessel ulcers | Venous insufficiency | Sensations of stiffness and discomfort | [ |
Currently available chronic wound treatments.
| Currently Available Chronic Wound Treatments | Advantages | Disadvantages | Applications | Is It | Does It | Refs. |
|---|---|---|---|---|---|---|
| Debridement | Prevent the expansion of the area of non-viable tissue while keeping the area of viable tissue stable | May cause discomfort for the patient | All chronic wounds | Yes | Yes | [ |
| Hyperbaric oxygen therapy | Increase the oxygen concentration in blood in the wound area and shortens the wound healing process | Require a specialist to apply it | All diabetic ulcers | Yes | No | [ |
| Ultrasound and electromagnetic therapy | Provide pain relief to the patient | Time-consuming | Venous and pressure ulcers | Yes | No | [ |
| Negative pressure wound therapy | Increase blood flow and moisture around the wound | Require a proper health facility and medical specialist | Certain types of venous and pressure ulcers | Yes | No | [ |
| Skin grafts | Widely used | Only used for large wounds | Large chronic wounds | Yes | No | [ |
Commonly used wound dressings for chronic wounds.
| Wound Dressing Types | Function | Application | Advantages | Disadvantages | Refs. |
|---|---|---|---|---|---|
| Films | Surround the wound area | Shallow chronic wounds | Provide high levels of moisture | No absorptive capacity | [ |
| Gauze | Debridement | Shallow chronic wounds | Cost-efficient | Need to be frequently changed | [ |
| Foam | Absorb fluids and gel-like molecules | High exuding chronic wounds | Non-adherent | Desiccate dry chronic wounds | [ |
| Wound | Moist wound area | Deep wounds | Non-adherent | May adhere to wounds | [ |
| Hydrocolloid dressings | Absorb the fluids and gel-like molecules | Low exuding chronic wounds | Provide high levels of moisture | Create an antibacterial | [ |
| Hydrogel dressings | Provide autolytic debridement | Low exuding chronic wounds | Provide high levels of moisture | May not be beneficial to use for high exuding wounds | [ |
Hybrid hydrogels as functional wound dressings.
| Base Component | Secondary Component | Functionality | Outcome(s) | Refs. |
|---|---|---|---|---|
| Chitosan | Dextran-dopamine | pH-responsive controlled drug release | Controlled release of silver nanoparticles (AgNPs) and deferoxamine in acidic environments | [ |
| Chitosan | Poly(vinyl alcohol) (PVA) | Antimicrobial effect | Enhanced re-epithelization | [ |
| Chitosan | Poly(d,l-lactide)-poly(ethylene glycol)-poly(d,l-lactide) (PLEL) | Thermo-sensitive | Catechol modified quaternized chitosan (QCS-C) enhanced tissue adhesion | [ |
| Chitosan | Hyaluronic acid (HA) | Adhesive properties | Catechol-containing hydrogels presented adhesion strength to the wet surfaces | [ |
| Chitosan | Alginate and Polydeoxyribonucleotide (PDRN)-loaded CaCO3 nanoparticle (PCNP) | Controlled gene delivery | PCNP improved the in situ delivery efficacy of PDRN | [ |
| Chitosan | Gelatin | Biodegradable | Uniformly interconnected 3D porous structures | [ |
| Chitosan | Oxidized HA-graft-aniline tetramer (OHA-AT) | Biodegradable | Accelerated wound healing by increasing granulation tissue thickness, collagen disposition and angiogenesis | [ |
| Chitosan | Arginine-based poly(ester urea urethane) (Arg-PEUU) | Anti-inflammatory activity | Methacrylate-modified chitosan (CS-GMA) and Arg-PEUU hybrid hydrogels exhibited an excellent antibacterial activity | [ |
| Chitosan | Decellularized extracellular matrix (dECM) and Gelatin | Antibacterial | Interconnected pore structure with high porosity promoted cell growth | [ |
| Chitosan | Gallic acid (GA) | Adhesive property | Exhibited favorable antioxidant properties, high biocompatibility, and haemocompatibility | [ |
| Chitosan | PVA and PEG | pH/glucose-triggered drug release | pH and glucose-responsive drug delivery activity | [ |
| Gelatin | Lipopeptide-surfactin (SF) | Angiogenic activity | GelMA-SF hydrogels promoted diabetic wound healing via regulating macrophage polarization and promoting angiogenesis | [ |
| Agar | Fumaric acid (FA) and incorporated Ag NPs | Antibacterial | Controlled Ag ion release and microbial growth inhibition | [ |
| Dextran | Poly(ethylene glycol) diacrylate (PEGDA) | Biodegradable | Slower degradation of the dextran hydrogel with the high content of nondegradable PEGDA and higher cross-linking density | [ |
| Dextran | PEG | Controlled release of immune stimulatory cargo proteins | Controlled release of cargo proteins | [ |
| Methylcellulose | Pluronic F-127 | Thermosensitive controlled release of MMP-9 siRNA | Down-regulation of MMP-9 expression | [ |
Figure 2Development of bioadhesive, antioxidant, and antimicrobial multifunctional chitosan-based hydrogels for wound dressings. (A) Schematic representation for modification of chitosan with gallic acid (CS-GA). (B) Demonstration for adhesion, stretching, and removal of CS-GA from the skin surface. (C) Adhesion strength comparison (Student’s t-test, **** p < 0.0001). and (D) ROS scavenging performance based on the amount of GA grafting (E) Antimicrobial activity of CS, GA, and CS with different GA contents (G1 < G2 < G3) against Escherichia coli (E. coli) and Staphylococcus aureus (S.A.). Reproduced with permission [58]. Copyright 2022 Elsevier.
Figure 3(A) Schematic representation for a pH-responsive chitosan based-hydrogel targeted for diabetic foot ulcer treatment. A hybrid hydrogel (Gel) was constructed between N-carboxyethyl chitosan (N-chitosan), hyaluronic acid–aldehyde (HA-ALD), and adipic acid dihydrazide (ADH). Insulin was loaded into the polymer solution and reversible dynamic bonds were provided by acylhydrazone and imine bonds (Gel+In). pH responsive properties were achieved with acylhydrazone bonds. (B) pH-responsive release behavior of insulin for 14 days (C) Quantitative analysis of the number of inflammatory cells at 4 and 12 days after the operation (Tukey’s post-hoc analysis, * p < 0.05) (D) Quantitative analysis for wound area measured on days 0, 4, 8, and 12 (Tukey’s post-hoc analysis, * p < 0.05, ** p < 0.01, *** p < 0.001 compared with control group; # p < 0.05 compared with the hydrogel group) (E) Masson trichrome staining to show collagen deposition on days 4 and 12 after the application of Gel and Gel+In to full thickness foot skin wounds on diabetic rats (W: Wound area, N: Normal tissue). Reproduced with permission [128]. Copyright 2021 Elsevier.
Figure 4(A) Schematic representation of the fabrication of a drug releasing hydrogel. Metformin hydrochloride (MH) and curcumin (Cur) incorporated in a copper-based hybrid composite hydrogel Cur/MH/HKUST-1@Gel for murine diabetic wound healing. (B) Representative wound closure images of diabetic mice treated with Cur, MH, HKUST-1, Gel, Cur/MH/HKUST-1, and Cur/MH/HKUST-1@Gel for 20 days. (C) H&E staining images exhibiting tissue granulation and (D) Immunofluorescence staining images of CD31 to show neovascularization in mice skin tissue upon treatment with different groups. Reproduced with permission [127]. Copyright 2022 Elsevier.
Commercially available hydrogel wound dressings for chronic wound healing.
| Commercial Name | Manufacturer | Contents | Chronic Wound Applications | Secondary Wound Dressing Requirement | Refs. |
|---|---|---|---|---|---|
| ActivHeal® | Advanced Medical | Primary wound dressing with 85% water | Cavity wounds | No | [ |
| AquaDerm™ | DermaRite Industries | 2-Acrylamido-2 methyl-1 | Minor burns | No | [ |
| DermaGauze™ | DermaRite Industries | Impregnated gauze with acrylate polymer | Both partial and full thickness chronic wounds | Yes | [ |
| DermaSyn® | DermaRite Industries | Vitamin E | Both partial and full thickness chronic wounds | No | [ |
| INTRASITE Gel | Smith and Nephew | Carboxymethyl cellulose | Diabetic foot ulcers | No | [ |
| MEDIHONEY® (adhesive hydrogel sheet) | Integra LifeSciences | Adhesive hydrogel sheet | Pressure ulcers | No | [ |
| Neoheal® Hydrogel | Kikgel | PEG | Low exuding scabs | No | [ |
| NU-GEL™ | Systagenix | Sodium alginate | Diabetic foot ulcers | No | [ |
| Purilon® | Coloplast | Calcium alginate | Pressure ulcers | No | [ |
| Restore Hydrogel | Hollister Incorporated | Gauze pad | Both partial and full thickness chronic wounds | No | [ |
| Simpurity™ Hydrogel | Safe n’Simple | Absorbent sheets Acrylate | First- and second-degree partial-thickness burns | No | [ |
| SOLOSITE Gel | Smith and Nephew | Carboxymethyl cellulose | Diabetic foot ulcers | No | [ |
| Suprasorb® G | Lohmann & | Acrylic polymers Polyethylene | Dry chronic wounds | Yes | [ |
| Woun’ Dres® | Coloplast | Carbomer | Low exuding chronic wounds | No | [ |